AlphAIalphai — Financial news for AI agents
BenzingaOCT 162 min read$WHWK

Whitehawk Therapeutics Stock Is Trading Higher Thursday: What's Going On? - Whitehawk Therapeutics (NASDAQ:WHWK)

Whitehawk Therapeutics, Inc. ( NASDAQ:WHWK ) shares are rising Thursday after the company announced a multi-year collaboration with Tempus AI Inc ( NASDAQ:TEM ) to support the development of its oncology pipeline. WHWK stock is racing ahead of the pack. Check the market position here.

Original reporting
Benzinga · Dylan Berman
Published Oct 16, 2025, 3:52 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Oct 16, 2025, 4:30 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
Whitehawk Therapeutics Stock Is Trading Higher Thursday: What's Going On? - Whitehawk Therapeutics (NASDAQ:WHWK) — source image
Source · www.benzinga.com
Decision brief

The 30-second read

$WHWKBullishMed
01

Why it matters

This strategic partnership is expected to bolster WHWK's development efforts, potentially leading to future revenue streams.

02

Market read

The news is highly relevant for investors in biotech and oncology sectors, especially those holding or considering WHWK.

03

What to watch

Potential overvaluation due to hype; broader market corrections could negate gains.

Timing: Immediate, as the news is recent and stock prices are reacting.

Background

Whitehawk Therapeutics announced a multi-year collaboration with Tempus AI Inc., aiming to advance its oncology pipeline.

Company-level read

Ticker impact

$WHWKBullishHigh confidence
Context

High relevance due to recent collaboration announcement and stock movement.

Expected impact

Moderate upward movement expected in the short to medium term.

Evidence & confidence

The collaboration signifies strategic advancement and potential revenue growth, which are typically bullish signals. The stock's recent rally supports this outlook.

$TEMNeutralMedium confidence
Context

Moderate relevance as the collaboration involves Tempus AI Inc., but the direct impact on TEM's stock is limited.

Expected impact

Limited or negligible impact on TEM's stock price.

Evidence & confidence

While the partnership is beneficial for TEM, it does not directly alter TEM's financial outlook significantly at this stage.

Market effects

Sector

Potential positive sentiment in biotech and pharmaceutical sectors, especially companies involved in oncology.

Regional

Limited to US markets with possible ripple effects in biotech indices.

Global

Minimal; primarily relevant to US-based biotech stocks.

Counterpoint

What could challenge this read

The rally may be short-lived if the collaboration does not lead to tangible clinical or financial milestones.

Key entities

  • Company
    Whitehawk Therapeutics

    A biotech firm focused on oncology therapeutics.

  • Company
    Tempus AI Inc.

    A technology company specializing in AI-driven healthcare solutions.

Read at source← All news

Related articles

AUG 7
$TEMMed

Why Is Tempus AI Stock Surging on Friday? - Tempus AI (NASDAQ:TEM)

Tempus AI Inc. (NASDAQ:TEM) shares rose about 11% on Friday, outperforming the Nasdaq and the Healthcare sector, amid an AI-healthcare sector rally. The move followed strong peer results, including Doximity’s fiscal Q1 revenue of $156.6 million, and a strategic collaboration with CellCarta adding Tempus to its CDx lab network. TEM traded near $50.95.

benzinga.com4 min
AUG 6
$WHWKMed

Whitehawk Therapeutics, Inc. (WHWK): Results of Operations and Financial Condition

Whitehawk Therapeutics, Inc. (WHWK) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 whwk-ex99_1.htm EX-99.1 EX-99.1 PRESS RELEASE Whitehawk Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights Phase 1 trials for HWK-007 and HWK-016 continue to enroll; the Phase 1 trial for HWK-206 is on track to initiate in Q3 2026 Cash, cas

SEC EDGAR 8-K4 min
AUG 3
$TEMMed

BTIG cuts Tempus AI stock price target to $70 on model update

BTIG cut its Tempus AI (NASDAQ:TEM) price target to $70 from $80 while keeping a Buy rating after the company’s Q2 2026 earnings call. Tempus AI reported 22% YoY revenue growth, raised 2026 revenue guidance to 25% to 26%, and posted $382.5M revenue with an adjusted EPS loss of $0.04. BTIG cited Tempus’s $1.5B Personalis deal with a $46 stock-price termination trigger.

investing.com3 min
JUL 31
$TEMMedAI 8/10

Dear Tempus AI Stock Fans, Mark Your Calendars for July 30

Tempus AI (NASDAQ: TEM) agreed to acquire Personalis (PSNL) for $16.25 per share in stock, valuing the deal at about $1.5 billion enterprise value net of Tempus’ existing stake, with closing expected late 2026 or early 2027. Tempus expects integration to expand MRD capabilities. After the July 20 announcement, TEM fell 7.74% intraday. In Q1, revenue rose 36.1% to $348.12M. Needham reiterated Buy at $75; consensus target is $66.75.

yahoo.com5 min
JUL 31
$TEMMedAI 8/10

Tempus AI Raises FY2026 Sales Guidance to $1.595B-$1.605B

Tempus AI (NASDAQ: TEM) has raised its full-year 2026 sales guidance, signaling robust demand for its artificial intelligence-driven healthcare solutions. The company updated its revenue outlook to a range of $1.595 billion to $1.605 billion, an increase from the previous guidance of $1.590 billion to $1.600 billion.

scanx.trade5 min
JUL 30
$TEMMedAI 8/10

Tempus AI Q2 Results: Revenue rises 22% YoY, stock slides

Tempus AI (NASDAQ: TEM) reported second-quarter revenue of $382.5 million, rising 22% year-over-year and surpassing Street consensus estimates of $379.7 million. Despite the top-line beat and a narrower-than-expected loss per share of four cents versus an estimated 14 cents loss, shares declined 2.4% in after-hours trading to $43.25.

scanx.trade5 min